PCVX logo

Vaxcyte, Inc. (PCVX) Selling, General & Administrative Expenses

Annual SG&A:

$92.90M+$32.20M(+53.05%)
December 31, 2024

Summary

  • As of today, PCVX annual SG&A is $92.90 million, with the most recent change of +$32.20 million (+53.05%) on December 31, 2024.
  • During the last 3 years, PCVX annual SG&A has risen by +$67.64 million (+267.80%).
  • PCVX annual SG&A is now at all-time high.

Performance

PCVX SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

Quarterly SG&A:

$0.00-$32.04M(-100.00%)
September 30, 2025

Summary

  • As of today, PCVX quarterly SG&A is $0.00, with the most recent change of -$32.04 million (-100.00%) on September 30, 2025.
  • Over the past year, PCVX quarterly SG&A has dropped by -$22.99 million (-100.00%).
  • PCVX quarterly SG&A is now -100.00% below its all-time high of $32.66 million, reached on March 31, 2025.

Performance

PCVX Quarterly SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

TTM SG&A:

-$6.52B-$657.20M(-11.21%)
September 30, 2025

Summary

  • As of today, PCVX TTM SG&A is -$6.52 billion, with the most recent change of -$657.20 million (-11.21%) on September 30, 2025.
  • Over the past year, PCVX TTM SG&A has dropped by -$6.60 billion (-8065.27%).
  • PCVX TTM SG&A is now -5863.96% below its all-time high of -$109.35 million.

Performance

PCVX TTM SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXincome statement metrics

Selling, General & Administrative Expenses Formula

SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development

PCVX Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+53.0%-100.0%-8065.3%
3Y3 Years+267.8%-100.0%-10000.0%
5Y5 Years+987.1%-100.0%-10000.0%

PCVX Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+267.8%-100.0%at low-344.7%at low
5Y5-Yearat high+987.1%-100.0%at low-1023.5%at low
All-TimeAll-Timeat high+1624.2%-100.0%at low-5864.0%at low

PCVX Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sep 2025
-
$0.00(-100.0%)
$93.25M(-19.8%)
Jun 2025
-
$32.04M(-1.9%)
$116.24M(+10.0%)
Mar 2025
-
$32.66M(+14.4%)
$105.68M(+13.7%)
Dec 2024
$92.90M(+53.1%)
$28.55M(+24.2%)
$92.90M(+13.5%)
Sep 2024
-
$22.99M(+7.1%)
$81.87M(+9.9%)
Jun 2024
-
$21.47M(+8.0%)
$74.49M(+10.4%)
Mar 2024
-
$19.89M(+13.5%)
$67.47M(+11.2%)
Dec 2023
$60.70M(+52.5%)
$17.53M(+12.3%)
$60.70M(+10.1%)
Sep 2023
-
$15.61M(+7.9%)
$55.13M(+9.3%)
Jun 2023
-
$14.46M(+10.3%)
$50.42M(+11.1%)
Mar 2023
-
$13.11M(+9.7%)
$45.38M(+14.0%)
Dec 2022
$39.81M
$11.95M(+9.7%)
$39.81M(+15.0%)
Sep 2022
-
$10.90M(+15.7%)
$34.63M(+14.5%)
Jun 2022
-
$9.42M(+24.8%)
$30.25M(+12.4%)
DateAnnualQuarterlyTTM
Mar 2022
-
$7.54M(+11.4%)
$26.92M(+6.6%)
Dec 2021
$25.26M(+57.7%)
$6.77M(+3.8%)
$25.26M(+8.5%)
Sep 2021
-
$6.52M(+7.3%)
$23.28M(+7.5%)
Jun 2021
-
$6.08M(+3.3%)
$21.65M(+16.3%)
Mar 2021
-
$5.88M(+22.8%)
$18.62M(+16.3%)
Dec 2020
$16.02M(+87.4%)
$4.79M(-2.2%)
$16.02M(+17.1%)
Sep 2020
-
$4.90M(+60.8%)
$13.68M(+21.1%)
Jun 2020
-
$3.05M(-7.2%)
$11.29M(+7.4%)
Mar 2020
-
$3.28M(+33.5%)
$10.51M(+23.0%)
Dec 2019
$8.55M(+58.6%)
$2.46M(-2.1%)
$8.55M(+40.3%)
Sep 2019
-
$2.51M(+10.9%)
$6.09M(+70.1%)
Jun 2019
-
$2.26M(+72.0%)
$3.58M(+172.0%)
Mar 2019
-
$1.32M
$1.32M
Dec 2018
$5.39M
-
-

FAQ

  • What is Vaxcyte, Inc. annual SG&A?
  • What is the all-time high annual SG&A for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. annual SG&A year-on-year change?
  • What is Vaxcyte, Inc. quarterly SG&A?
  • What is the all-time high quarterly SG&A for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. quarterly SG&A year-on-year change?
  • What is Vaxcyte, Inc. TTM SG&A?
  • What is the all-time high TTM SG&A for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. TTM SG&A year-on-year change?

What is Vaxcyte, Inc. annual SG&A?

The current annual SG&A of PCVX is $92.90M

What is the all-time high annual SG&A for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high annual SG&A is $92.90M

What is Vaxcyte, Inc. annual SG&A year-on-year change?

Over the past year, PCVX annual SG&A has changed by +$32.20M (+53.05%)

What is Vaxcyte, Inc. quarterly SG&A?

The current quarterly SG&A of PCVX is $0.00

What is the all-time high quarterly SG&A for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high quarterly SG&A is $32.66M

What is Vaxcyte, Inc. quarterly SG&A year-on-year change?

Over the past year, PCVX quarterly SG&A has changed by -$22.99M (-100.00%)

What is Vaxcyte, Inc. TTM SG&A?

The current TTM SG&A of PCVX is -$6.52B

What is the all-time high TTM SG&A for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high TTM SG&A is -$109.35M

What is Vaxcyte, Inc. TTM SG&A year-on-year change?

Over the past year, PCVX TTM SG&A has changed by -$6.60B (-8065.27%)
On this page